Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

Explore the link between histamine and migraine. Learn about histamine intolerance, acute treatments like Benadryl, and ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

Robby holding a baby on The Pitt season 2 - Warrick Page/HBO Max When "The Pitt" dropped on HBO Max (née Max) in January 2025 ...

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...

The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults. This marks the first new treatment for motion sickness in over ...

CHS is a condition marked by abdominal pain, nausea, and persistent vomiting linked to prolonged heavy cannabis use. This ...

US FDA approves Vanda Pharma’s Nereus, an oral NK-1 receptor antagonist for prevention of vomiting induced by motion: Washington Friday, January 2, 2026, 15:00 Hrs [IST] Vanda P ...

Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo. ・Vanda is also advancing Tradipitant in clinical development for ...

Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.